Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/82767
Or use following links to share this resource in social networks: Recommend this item
Title Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Authors Jotte, R.
Cappuzzo, F.
Vynnychenko, Ihor Oleksandrovych  
Stroyakovskiy, D.
Rodríguez-Abreu, D.
Hussein, M.
Soo, R.
Conter, H.J.
Kozuki, T.
Huang, Kuan-Chieh
Graupner, V.
Sun, S.W.
Hoang, T.
Jessop, H.
McCleland, M.
Ballinger, M.
Sandler, A.
Socinski, M.A.
Keywords Squamous NSCLC
Atezolizumab
Nab-paclitaxel
Carboplatin
IMpower131
Type Article
Date of Issue 2020
URI https://essuir.sumdu.edu.ua/handle/123456789/82767
Publisher IASLC
License Creative Commons Attribution 4.0 International License
Citation Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. Journal of Thoracic Oncology. 2020; 15(8): 1351-1360. https://doi.org/10.1016/j.jtho.2020.03.028
Abstract Introduction: Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti–PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated atezolizumab with platinum-based chemotherapy in stage IV squamous NSCLC. Methods: A total of 1021 patients were randomized 1:1:1 to receive atezolizumabþcarboplatinþpaclitaxel (AþCP) (n ¼ 338), atezolizumabþcarboplatinþnab-paclitaxel (AþCnP) (n ¼ 343), or carboplatinþnab-paclitaxel (CnP) (n ¼ 340) for four or six 21-day cycles; patients randomized to the AþCP or AþCnP arms received atezolizumab maintenance therapy until progressive disease or loss of clinical benefit. The coprimary end points were investigatorassessed progression-free survival (PFS) and overall survival (OS) in the intention-to-treat (ITT) population. The secondary end points included PFS and OS in PD-L1 subgroups and safety. The primary PFS (January 22, 2018) and final OS (October 3, 2018) for AþCnP versus CnP are reported. Results: PFS improvement with AþCnP versus CnP was seen in the ITT population (median, 6.3 versus 5.6 mo; hazard ratio [HR] ¼ 0.71, 95% confidence interval [CI]: 0.60–0.85; p ¼ 0.0001). Median OS in the ITT population was 14.2 and 13.5 months in the AþCnP and CnP arms (HR ¼ 0.88, 95% CI: 0.73–1.05; p ¼ 0.16), not reaching statistical significance. OS improvement with AþCnP versus CnP was observed in the PD-L1–high subgroup (HR ¼ 0.48, 95% CI: 0.29–0.81), despite not being formally tested. Treatment-related grade 3 and 4 adverse events and serious adverse events occurred in 68.0% and 47.9% (AþCnP) and 57.5% and 28.7% (CnP) of patients, respectively. Conclusions: Adding atezolizumab to platinum-based chemotherapy significantly improved PFS in patients with first-line squamous NSCLC; OS was similar between the arms.
Appears in Collections: Наукові видання (МІ)

Views

China China
1
Finland Finland
1
Lithuania Lithuania
1
Ukraine Ukraine
26
United Kingdom United Kingdom
1
United States United States
303
Vietnam Vietnam
91

Downloads

China China
28
Germany Germany
61
India India
1
Lithuania Lithuania
1
Ukraine Ukraine
23
United Kingdom United Kingdom
1
United States United States
305
Vietnam Vietnam
1

Files

File Size Format Downloads
Jotte_Atezolizumab_2020.pdf 543,87 kB Adobe PDF 421

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.